priors.science/reviews/sacubitril-and-valsartan

Sacubitril and Valsartan

The current evidence on 13 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

13claims tracked
56primary papers reviewed
6 Jul 2026latest evidence review
Weeklyre-scored against new papers
4 Established · 8 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableSacubitril/valsartan reduces CV death and HF hospitalisation versus enalapril in HFrEFHfrefEstablished97%4
StableSacubitril/valsartan is contraindicated within 36 hours of ACE inhibitor use due to angioedema riskSafEstablished96%4
StableSacubitril/valsartan reduces all-cause mortality versus enalapril in HFrEFHfrefEstablished91%4
StableSacubitril/valsartan reduces NT-proBNP more than ACEi in HFrEFExtEstablished87%4
StableSacubitril/valsartan causes more symptomatic hypotension than ACE inhibitorsSafLikely84%4
StableSacubitril/valsartan does not reduce CV events after acute myocardial infarction versus ACEiExtLikely80%4
StableSacubitril/valsartan does not significantly reduce primary outcome in HFpEF overallHFPEFLikely78%4
StableSacubitril/valsartan does not worsen renal function versus ACEi in HFrEFSafLikely78%4
StableSacubitril/valsartan reverses left ventricular remodelling more than ACEi in HFrEFExtLikely74%4
StableEarly in-hospital sacubitril/valsartan initiation improves post-hospitalisation outcomesHfrefLikely72%4
StableSacubitril/valsartan benefits HFpEF patients with ejection fraction below normal rangeHFPEFLikely68%4
StableFemale patients derive greater benefit from sacubitril/valsartan in HFpEF than malesHFPEFUncertain62%4
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic